Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma Announces...

    Sun Pharma Announces Data from Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting

    Written by supriya kashyap kashyap Published On 2017-03-03T10:09:08+05:30  |  Updated On 3 March 2017 10:09 AM IST




    Mumbai : Sun Pharmaceutical Industries Ltd announced that several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, will be presented at the 2017 Annual American Academy of Dermatology (AAD) Meeting taking place March 3-7 in Orlando, Florida.


    "Not all people with psoriasis respond to currently available therapies or are able to maintain long-term symptom control. We are looking forward to sharing new and continued insights about tildrakizumab at AAD and upcoming meetings," said Jesper Jensen, Executive Vice President, Biologics and Dermatology, Sun Pharma. "With origins in dermatology that stretch back more than 30 years, we are committed to patients suffering from skin conditions. At Sun Dermatology, we care to make a difference."









    Tildrakizumab data analyses being presented at AAD include:




    • Tildrakizumab, a Selective Anti-IL-23 Monoclonal Antibody, Is Effective in Subjects With Chronic Plaque Psoriasis Who Do Not Adequately Respond to Etanercept – Poster 5252 (Pearls of the Symposium Session on Friday, March 3rd from 2:30 PM to 2:40 PM)

    • Efficacy of Tildrakizumab, an Anti-IL23p19 Monoclonal Antibody, Stratified by Prior Exposure to Biologics in a Randomized, Placebo-Controlled Phase 3 Clinical Trial – Poster 5111 (Psoriasis & Other Papulosquamous Disorders Section on Sunday, March 5th from 9:20 AM to 9:25 AM)

    • Maintenance of Treatment Response in Chronic Plaque Psoriasis Patients Continuing Treatment or Discontinuing Treatment With Tildrakizumab in a 64-Week, Randomized Controlled, Phase 3 Trial Poster 4855 (Psoriasis & Other Papulosquamous Disorders Section onSunday, March 5th from 11:35 AM to 11:40 AM)

    • The Effect of Tildrakizumab, a High-Affinity, Selective Anti-IL23p19 Monoclonal Antibody, on Cytochrome P450 Metabolism – Poster 4792 (Pharmacology Section on Sunday, March 5th from 12:55 PM to 1:00 PM)


    Over 1,800 patients across more than 200 clinical sites participated in the tildrakizumab Phase-3 pivotal trials (reSURFACE 1 and 2). Data were presented for the first time demonstrating results through 28 weeks of treatment at the European Academy of Dermatology and Venerology (EADV) Congress in October 2016. Regulatory filings for tildrakizumab in the U.S. and Europe are proceeding as planned.






    American Academy of DermatologyEADVEuropean Academy of Dermatology and VenerologyJesper JensenSun PharmaTildrakizumab
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok